Begelomab

Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy[1][2].

Product Specifications

CAS Number

[1403744-56-8]

Product Name Alternative

SAND-26

UNSPSC

12352203

Target

Dipeptidyl Peptidase

Type

Inhibitory Antibodies

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/begelomab.html

Purity

95.0

Solubility

H2O

Smiles

[Begelomab]

Molecular Weight

(144.78 kDa)

References & Citations

[1]Lorenzo RD, et, al. Begelomab for severe refractory dermatomyositis: A case report. Medicine (Baltimore) . 2021 Mar 5;100 (9) :e24372. |[2]Ojha R, et, al. Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2. Hum Immunol. 2022 Apr;83 (4) :346-355.